Immunomodulation Using VB-201 to Reduce Arterial Inflammation in Treated HIV - VITAL HIV Trial
Status:
Not yet recruiting
Trial end date:
2027-07-01
Target enrollment:
Participant gender:
Summary
This study is a double blinded, placebo-controlled, randomized, parallel group study,
designed to compare the efficacy and safety of VB-201 80mg taken orally once daily to placebo
for anti-inflammation in HIV-infected subjects.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Priscilla Hsue, MD
Collaborators:
University of California, Los Angeles University of Utah